Kapusta Matthew C sold $1.8M of QURE

Kapusta Matthew C (CEO, Managing Director) sold 35,412 shares of uniQure N.V. (QURE) at an average of $50.02 ($50.00–$50.02, $1.77M total) across 2 trades over 2026-06-24 to 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kapusta Matthew C
Published Jun 26, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Neutral
medium confidence
Mentioned
$QURE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale of 35,412 shares at ~$50.0162 weighted average across 2026-06-24 to 2026-06-25, totaling ~$1.77M, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor QURE for follow-on insider activity, but this specific filing does not introduce new fundamental catalysts.

03

What to watch

Insider sales can be offset by other insider buys or by non-informational motives; this filing alone lacks context on total insider activity and does not include any new company guidance.

Relevance 5/10Novelty 4/10Timing: after-hours/filing timestamp (SEC EDGAR filed 2026-06-26 17:15:29-04:00)

Background

The article is an SEC Form 4 insider transaction disclosure for uniQure N.V. (QURE) by CEO/Managing Director Matthew C Kapusta.

Company-level read

Ticker impact

$QURENeutralMedium confidence
Context

uniQure CEO Matthew C Kapusta sold about $1.77M of QURE shares in two open-market trades under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless accompanied by other news.

Evidence & confidence

Form 4 shows an open-market sale with a stated 10b5-1 plan and a modest insider-sale size relative to typical liquidity; no new operating/clinical/regulatory facts are provided.

Market effects

No sector-wide read-through; this is company-specific insider transaction reporting.

None indicated; filing is US-based disclosure for a Netherlands-domiciled issuer.

Minimal; no deal, trial, or regulatory development affecting broader markets.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than a bearish view.

Key entities

  • uniQure N.V.

    Subject of the Form 4 insider transaction; CEO Matthew C Kapusta sold shares under a 10b5-1 plan.

  • Kapusta Matthew C

    CEO, Managing Director; reported open-market sale of 35,412 QURE shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREMedAI 8/10

QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?

uniQure N.V. (QURE) shares rose 17.5% in a month, outperforming the industry and S&P 500. The rally was driven by FDA acceptance of its Huntington's disease drug application, ifezuntirgene inilparvovec, for review. Despite weaker Q3 2026 results, investors focus on the drug's potential. QURE's cash position is strong, with $768.4M as of Sept. 30, 2026, expected to fund operations through 2030.

$QUREMedAI 8/10

uniQure Prepares for Potential FDA Panel on Huntington’s Gene Therapy After Priority Review Nod

uniQure (QURE) is preparing for a potential FDA panel review of its gene therapy AMT-130 for Huntington's disease after receiving a priority review nod. The company presented 48-month data showing treated patients had less functional decline than untreated ones, though control group limitations were noted. uniQure plans a confirmatory study and is preparing for a potential launch, with $780 million in cash to fund operations into 2030.

$QUREHighAI 9/10

Key facts: AMT-130 Priority Review; 48-Month Data; Q3 Revenue +40%

uniQure's AMT-130 was accepted for FDA Priority Review with a decision goal of May 1, 2027. The U.K. validated its marketing application. 48-month data showed slowed Huntington’s disease progression. Q3 2026 revenue rose 40.4% to $5.2 million, below estimates, with net loss narrowing to $61.2 million. Cash reserves were $768.4 million.

MedAI 8/10

uniQure N.V. Q3 2026 Earnings Call Summary

uniQure N.V. reported that the FDA accepted its AMT-130 BLA with priority review for Huntington's disease, citing 36-month data showing a 60% slowing in TFC decline. The company plans a focused commercial launch targeting 15-30 priority institutions. Management expects the confirmatory study to be underway by the 2027 PDUFA date and cash runway to extend into 2030. SG&A expenses increased by $4.5 million year-over-year.

$QUREMed

uniQure (QURE) Q3 2026 Earnings Call Transcript

uniQure (QURE) reported progress in its Q3 2026 earnings call. The company's AMT-130 therapy for Huntington's disease showed a 75% slowing of disease progression in trials. The FDA is reviewing the Biologics License Application (BLA) with a PDUFA date of May 1, 2027. uniQure is preparing for a potential U.S. launch in 2027 and advancing its pipeline, including studies for AMT-260 and AMT-191. The company is also building its commercial teams ahead of the planned launch.